EUVIMEDEUVIMED entdecken
Crossref

Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

Sunil Lakhwani, María Victoria Mateos, Joaquín Martínez-López, Bruno Paiva, Laura Rosiñol Dachs, Rafael Martínez, Albert Oriol, Joan Bargay, Yolanda González-Montes, Mercedes Gironella, Cristina Encinas, Jesús Martín und 27 weitere

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-06031-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Sunil Lakhwani und 38 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario de Canarias, Universidad de La Laguna, Tenerife, Spain. sunillakhwani@hotmail.com. Hauptthemen laut MEDLINE: Multiple Myeloma, Neoplasm, Residual, Dexamethasone, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Information on the prognostic value of immunoparesis (IP) recovery in multiple myeloma (MM) patients has been only generated in some observational and retrospective studies. We have evaluated the prognostic impact of IP recovery and its association with minimal residual disease (MRD) in a series of 113 newly diagnosed transplant-ineligible (NDTI) patients, that received fix duration treatment (18 cycles of VMP/lenalidomide-dexamethasone) within the PETHEMA/GEM2010MAS65 trial and who achieved CR or VGPR. Immunoglobulin levels were measured at diagnosis, at the end of treatment (after cycle 18th) and during subsequent follow up whereas MRD was analyzed only at the end of the treatment (after cycle 18th). We found that patients who had IP at diagnosis and recovered it during or after treatment had longer progression free survival (PFS) [p < 0.001; HR 0.32 (0.19-0.52)] and longer overall survival (OS) [p = 0.007; HR 0.40 (0.20-0.80)] compared to those who failed to recover it. When we analyzed IP recovery in MRD negative patients, we found that those cases with IP recovery had longer PFS [p = 0.007; HR 0.31 (0.13-0.76)] and longer OS [p = 0.012; HR 0.21 (0.06-0.80)] as compared to MRD negative patients but without IP recovery. In conclusion, IP recovery confers better prognosis in NDTI-MM patients with fixed duration treatment who achieve CR or VGPR and the prognostic value of MRD can be complemented when combined with IP recovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaNeoplasm, ResidualDexamethasoneAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleAgedMiddle AgedPrognosisLenalidomidePrednisoneRetrospective StudiesSurvival RateAged, 80 and over

Stichwörter der Autor:innen

ImmunoglobulinImmunoparesisMinimal residual diseaseMyeloma

Substanzen

DexamethasoneLenalidomidePrednisone

Autor:innen und Institutionen

  • Hospital Universitario de Canarias, Universidad de La Laguna, Tenerife, Spain. sunillakhwani@hotmail.com.
  • University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain.
  • Hospital Universitario 12 de Octubre, Universidad Complutense, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
  • Cancer Center Clínica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain.
  • Amyloidosis and Myeloma Unit, Hospital Clínic, Barcelona, Spain.
  • Hospital Universitario San Carlos, Madrid, Spain.

Zitieren

APA

Lakhwani, S., Mateos, M. V., Martínez-López, J., Paiva, B., Rosiñol Dachs, L., Martínez, R., Oriol, A., Bargay, J., González-Montes, Y., Gironella, M., Encinas, C., Martín, J., Jarque, I., Granell, M., Abella, E., García-Mateo, A., Hernández-Rivas, J. Á., Ramila, E., Krsnik, I., …, & Hernández, M. T. (2024). Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease. Annals of Hematology. https://doi.org/10.1007/s00277-024-06031-0

Vancouver

Lakhwani S, Mateos MV, Martínez-López J, Paiva B, Rosiñol Dachs L, Martínez R, et al. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease. Annals of Hematology. 2024. doi:10.1007/s00277-024-06031-0

BibTeX
@article{Lakhwani2024,
  author = {Lakhwani, Sunil and Mateos, María Victoria and Martínez-López, Joaquín and Paiva, Bruno and Rosiñol Dachs, Laura and Martínez, Rafael and Oriol, Albert and Bargay, Joan and González-Montes, Yolanda and Gironella, Mercedes and Encinas, Cristina and Martín, Jesús and Jarque, Isidro and Granell, Miquel and Abella, Eugenia and García-Mateo, Aránzazu and Hernández-Rivas, José Ángel and Ramila, Elena and Krsnik, Isabel and Casado Montero, Luis Felipe and De Arriba, Felipe and Palomera, Luis and Sampol, Antonia and Moraleda, José María and Casanova, María and Delgado, Pilar and Lafuente, Ana and Amutio, Elena and López-Martínez, Aurelio and Altés, Albert and Ruíz, M Ángeles and Alegre, Adrián and Lopez-Anglada, Lucia and De La Cruz, Javier and Alonso Fernández, Rafael and Bladé Creixenti, Joan and Lahuerta, Juan-José and San-Miguel, Jesús and Hernández, Miguel-Teodoro},
  title = {Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-06031-0}
}
Kostenlos starten →